16.61

0.78% -0.13

After Hours: 16.62 0.01 +0.06%

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $16.61, with a volume of 211.09K. It is down -0.78% in the last 24 hours and down -9.53% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Previous Close:

$16.74

Open:

$16.86

24h Volume:

211.09K

Relative Volume:

0.45

Market Cap:

$738.36M

Revenue:

$9.00M

Net Income/Loss:

$-80.61M

P/E Ratio:

-7.4046

EPS:

-2.2432

Net Cash Flow:

$-82.35M

1W Performance:

-5.95%

1M Performance:

-9.53%

6M Performance:

+92.02%

1Y Performance:

+311.14%

1-Day Range:

$16.60

$17.33

1-Week Range:

$14.72

$18.25

52-Week Range:

$3.79

$24.00

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

510-806-1445

Address

5885 HOLLIS STREET, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	16.61	744.14M	9.00M	-80.61M	-82.35M	-2.2432
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Needham	Buy
Feb-25-26	Initiated	Oppenheimer	Outperform
Feb-18-26	Upgrade	Jefferies	Hold → Buy
Jan-27-26	Initiated	Piper Sandler	Overweight
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-22-25	Upgrade	Citigroup	Neutral → Buy
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

May 25, 2026

BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

May 25, 2026

May 22, 2026

BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan

May 22, 2026

May 20, 2026

Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey

May 20, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga

May 20, 2026

May 18, 2026

Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus

May 18, 2026

May 15, 2026

Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan

May 15, 2026

BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent

May 15, 2026

Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan

May 15, 2026

May 14, 2026

BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union

May 14, 2026

Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView

May 14, 2026

BioAge Labs : BIOA - 24/7 Wall St.

May 14, 2026

Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan

May 14, 2026

May 13, 2026

BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN

May 13, 2026

BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo

May 13, 2026